TTRA Drugs & Devices
Endo Axiom Pty Ltd
Beyond the Needle: Evaluating a safe and smart oral insulin in type 1 diabetes
Endo Axiom Pty Ltd
Beyond the Needle: Evaluating a safe and smart oral insulin in type 1 diabetes
We have developed and commercialised a novel drug delivery platform that allows insulin to be taken as a tablet. It is a smart insulin, i.e. it responds to the body’s own glucose levels to release insulin and provide effective blood glucose management with specific advantages critical to winning marketshare over competition.
Advantages include:
- Fewer adverse hypoglycaemic events (low blood glucose) and no weight gain;
- Cost effectiveness compared to current standards of care;
- Implementable with newly diagnosed patients (i.e. titratable);
- Convenient and cost-effective storage and transportation of product at room temperature.
Our highly positive dataroom shows: 1) oral/smart insulin effectiveness in animal models of diabetes and non-human primates (4), 2) a good-manufacturing-practice (GMP) product made in Australia, and 3) certified pre-clinical toxicity testing. This project is currently in phase 1a trials with this grant supporting a phase 1b clinical trial with Australian type 1 diabetic (T1D) patients.
- TTRA Project: Drugs
- State: NSW
- Project Partner: The University of Sydney
- Project Lead: Dr Nicholas Hunt
- TTRA Funding: $1,079,424.00
- Co-Contribution: $1,623,369.00 cash; $220,112.00 in-kind
- Project term: 1 Feb 2026 – 29 Feb 2028
Website LinkedIn
